AstraZeneca: Q2 2014 Results (AstraZeneca) - Aug 2, 2014 - Anticipated completion of enrollment in P2 trial for moderate to severe ulcerative colitis in Q4 2014; Anticipated completion of P2 trial for moderate to severe ulcerative colitis in Q1 2015; Anticipated external presentation of data from P2 trial for moderate to severe ulcerative colitis in 2016; Anticipated completion of enrollment in P2 trial for moderate to severe Crohn’s disease in Q4 2014; Anticipated completion of P2 trial for moderate to severe Crohn’s disease in Q2 2015; Anticipated external presentation of data from P2 trial for moderate to severe Crohn’s disease in 2016; Anticipated completion of P2 trial in Japan for moderate to severe ulcerative colitis in Q1 2015
Anticipated enrollment status • Anticipated P2 data • Anticipated trial completion date • Immunology • Inflammatory Bowel Disease
|